Anthera Pharmaceuticals, Inc.
ANTH
ANTH was delisted on the 27th of June, 2018.
74 hedge funds and large institutions have $70.5M invested in Anthera Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 31 increasing their positions, 14 reducing their positions, and 5 closing their positions.
121% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 14
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
3% more funds holding
Funds holding: 72 → 74 (+2)
14% less call options, than puts
Call options by funds: $558K | Put options by funds: $651K
15% less capital invested
Capital invested by funds: $83M → $70.5M (-$12.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.73M |
| 2 |
State Street
Boston,
Massachusetts
|
+$835K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$530K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$339K |
| 5 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$265K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Gruss Capital Management
New York
|
-$2.56M |
| 2 |
SCM
Sio Capital Management
New York
|
-$1.84M |
| 3 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$477K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$349K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$345K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
AQR Capital Management
Greenwich,
Connecticut
| – | -$120K | -4,136 | Closed |
|
|
HCM
77
Highbridge Capital Management
New York
| – | -$99K | -3,429 | Closed |
|
|
GT
78
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$10K | -375 | Closed |
|
ANTH Hedge Fund Activity: Q2 2016 in Review
74 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q2 2016, worth a combined $70.5M — down 15% from $83M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ANTH positions and 5 closed out — a net gain of 2 holders — while 31 added to existing stakes and 14 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.73M. The largest seller was Gruss Capital Management, exiting entirely with an estimated $2.56M sold.
- 74 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q2 2016, up from 72 in Q1 2016.
- Funds reported $70.5M of Anthera Pharmaceuticals, Inc. stock for Q2 2016, down 15% quarter-over-quarter.
- 7 funds opened new Anthera Pharmaceuticals, Inc. positions in Q2 2016 and 5 closed out, a net change of +2 holders.
- The largest Anthera Pharmaceuticals, Inc. buyer in Q2 2016 was Fidelity Investments, an estimated $1.73M added.
- The largest Anthera Pharmaceuticals, Inc. seller in Q2 2016 was Gruss Capital Management, an estimated $2.56M sold.
Based on aggregated 13F filings for Q2 2016.